Sanovel Brings Its Experience of Over 40 Years to the Field of Urology

Sanovel, one of the established companies of the Turkish pharmaceutical industry, is adding urology to the treatment areas in which it operates with its experience of over 40 years. The company aims to expand its activities for healthcare professionals by starting its work in the field of urology as of October 2026.

Standing alongside healthcare professionals in different treatment areas, Sanovel will focus on urological diseases and scientific developments in this field in the new period.

Sanovel's new focus: Urology

Urological diseases are among the health problems that are common in society and can significantly affect individuals' daily lives. One of Sanovel's priority focuses in the field of urology will be overactive bladder (OAB).

Overactive bladder is defined as a clinical condition characterized by symptoms such as sudden urge to urinate, frequent urination and nighttime urination, which in some people may also be accompanied by urinary incontinence.

Within the scope of its activities in the field of urology, Sanovel plans to continue its work for healthcare professionals by closely monitoring scientific developments and health needs.

Over 40 years of experience is being carried into new treatment areas

Sanovel is expanding its work in the field of health by adding urology to the treatment areas in which it operates. While continuing its activities in different therapeutic areas with the strength gained from its experience of over 40 years, the company aims to contribute to the health ecosystem with new areas of expertise.

In a statement made by Sanovel, it was noted that the company will resolutely continue its future-oriented work through its activities in the field of urology.

About Sanovel

Founded in 1983 by Pharmacist Erol Toksöz, Sanovel operates with a portfolio consisting of more than 60 brands and over 180 products. The company has an annual production capacity of 200 million boxes.

Holding European cGMP (Good Manufacturing Practices) certification and approval from the US Food and Drug Administration (FDA), Sanovel also continues its activities in R&D and patent/intellectual property rights.

The company, which delivers its products to more than 50 countries across 5 continents, is among the organizations that bring the first equivalent (generic) products to market in different treatment areas. With approximately 1,750 employees, Sanovel continues to contribute to the Turkish pharmaceutical industry and the Turkish economy.